August 5, 2019 08:50 AM EDT

Racing after the leaders, Eli Lilly's migraine drug clears another pivotal study

Natalie Grover

Reporter

A month after securing approval for cluster headaches, Lilly’s $LLY migraine drug Emgality has scored in a late-stage trial as a preventive treatment for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Racing after the leaders, Eli Lilly's migraine drug clears another pivotal study

Natalie Grover

Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Ozempic makes list for next round of Medicare drug price negotiations

What Trump's CMS can and can't change with the second round of drug price negotiations

Broad Institute paper offers potential new framework for treating Huntington’s disease

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Rac­ing af­ter the lead­ers, Eli Lil­ly's mi­graine drug clears an­oth­er piv­otal study

Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Racing after the leaders, Eli Lilly's migraine drug clears another pivotal study